Articles On Kazia Therapeutics (ASX:KZA)

Edison has increased its valuation to A$375 million or A$2.83 per basic share from A$346 million or A$2.68 per basic share mainly due to rolling forward its Net Present Value (NPV).

SYDNEY, Oct. 6, 2021 /PRNewswire/ — Kazia Therapeutics Limited (NASDAQ: KZIA; ASX: KZA), an oncology-focused drug development company, is pleased to announce that CEO, Dr James Garner, will be presenting at the LD Micro Main Event, to be he...

SYDNEY, Sept. 11, 2021 /PRNewswire/ — Kazia Therapeutics Limited (NASDAQ: KZIA; ASX: KZA), an oncology-focused drug development company, is pleased to announce that CEO, Dr James Garner, will be presenting at the HC Wainwright 23rd Annua...

ShareCafeHidden Gems Webinar Recap – CYP, AT1, NSB & KZA Catch up on the full webinar with presentations from Cynata Therapeutics (ASX: CYP), Atomo Diagnostics (ASX: AT1), NeuroScientific (ASX: NSB) & Kazia Therapeutics (ASX: KZA)...

ShareCafeA high quality pipeline of cancer drugs James Garner – Managing Director & CEO – Kazia Therapeutics Limited is an innovative oncology-focused biotechnology company. Kazia is working to develop therapies across a range of on...

Although earnings results were the main theme in August, there were also some notable healthcare breakthroughs on the ASX. Dimerix (ASX:DXB) jumped 45% during the month after announcing the commencement of ACTION 3, a Phase III study in pat...

“The second calendar quarter has been a busy and productive period for Kazia, as we bed down three substantial cross-border licensing deals,” says CEO.

Kazia says its future success will be measured by commercialisation milestones after the company recorded its maiden revenue in the 2021 financial year.

It’s been a mixed two weeks for small-cap health companies, with only 45 companies gaining ground, 76 losing it and 23 flatlining. Rhinomed (ASX:RNO) was the biggest gainer, up a massive 85% for the fortnight after scoring a contract with N...

The ASX 200 health stocks index is tracking the broader index well over the past two weeks. Both the XHJ Health Sector and the ASX 200 benchmark rose by 3% over this period. A handful of ASX health stocks have seen their prices skyrocket du...

All upfront payments from outbound partnering transactions in the first quarter have been received by Kazia.

SYDNEY, July 21, 2021 /PRNewswire/ — Kazia Therapeutics Limited (NASDAQ: KZIA; ASX: KZA), a leading drug development company in the field of brain cancer, today recognizes Glioblastoma (GBM) Awareness Day and calls for a greater focus on re...

It’s been a mixed two weeks for small-cap health companies, with only 38 companies gaining ground, 74 losing it and 21 flatlining. Analytica Limited (ASX:ALT) was the biggest gainer, up 25% from 8 to 20 July, followed by  Rhinomed (ASX:RNO)...

It’s been a mixed two weeks for small-cap health companies, with 60 companies gaining ground and 52 losing it – and 21 flatlining. Botanix Pharma Ltd (ASX:BOT) was the biggest gainer, up 38% from 23 June to 7 July, and Suda Pharmaceuticals...

The fortunes of ASX healthcare shares can often swing on one momentous milestone. Examples of such a make-or-break event could be a breakthrough invention, successful product trial, or regulatory approval (or rejection). Such incidents can...

SYDNEY, June 30, 2021 /PRNewswire/ — Kazia Therapeutics Limited (NASDAQ: KZIA; ASX: KZA), an oncology-focused drug development company, is pleased to provide an update on recent progress with its two pipeline assets, paxalisib and EVT801...

The GBM AGILE pivotal study of paxalisib is recruiting ahead of expectations, with almost 25 sites now open to the paxalisib arm in the US across several prestigious centres.

Summary Afterpay jumps on plans to expand reach with U.S. merchants Althea enters South African cannabis market worth US$667 million Bluechiip shares close strong on a settlement agreement with Labcon North America The S&P/ASX...

Summary The ASX 200 closed lower for the second day in a row, falling 0.32% to 7,275.30. The ASX health care and energy stocks were among top losers, while tech and consumer staples emerged as top gainers. Australian retailer Woolwort...

A Kazia-licensed oncology drug has secured manufacturing patents in two key countries, providing an additional layer of protection for the treatment candidate over the next 15 years.

Oncology-focused drug development company Kazia Therapeutics (ASX:KZA) has announced the grant of patents by the respective agencies of the US and India for the manufacturing process for paxalisib.

Recent advances in our still-shallow understanding of the human brain have led to a renewed interest in companies that focus on neuroscience. The most famous neuroscience startup, Elon Musk’s Neuralink, is probably the first company that co...

SYDNEY, June 15, 2021 /PRNewswire/ — Kazia Therapeutics Limited (NASDAQ: KZIA; ASX: KZA), an oncology-focused drug development company, is pleased to announce that it has entered a collaboration with the Joan & Sanford I Weill Medica...

Shares in Kazia Therapeutics Ltd (ASX: KZA) lifted today after news its investigational drug Paxalisib will be part of another study for the treatment of brain cancer. At market close, the Kazia share price is $1.40 – 6.87% higher than its...

A new study will evaluate the efficacy of Kazia’s paxalisib candidate in patients with newly diagnosed or recurrent glioblastoma when combined with a ketogenic diet and metformin.

ShareCafeAlzheimer’s Decision Sends Positive Message to Aussie Biotechs The US Food and Drug Administration’s landmark but controversial approval of a new treatment for Alzheimer’s disease suggests a sea change in the regulator’s attitude t...

Here’s our fortnightly wrap of all the news driving ASX health stocks. The healthcare sector has returned 2.3 per cent for the last two weeks, compared to the broader market which rose by 2.7 per cent. The biggest news globally was out of U...

SYDNEY, June 7, 2021 /PRNewswire/ — Kazia Therapeutics Limited (NASDAQ: KZIA; ASX: KZA), an oncology-focused drug development company, is pleased to announce that a phase II study of Kazia’s investigational new drug, paxalisib, in primar...

The Kazia Therapeutics Ltd (ASX: KZA) share price is edging lower, down 2% in morning trade. Below we take a look at the oncology-focused drug development company’s latest clinical trial update. What update did Kazia provide? Kazia Therape...

The DFCI study (NCT04906096) is an open-label phase II clinical trial of paxalisib in PCNSL and is expected to recruit up to 25 patients and up to two years to complete.

During the March quarter, the oncology-focused drug development company saw maiden revenue of A$5.3 million and its cash position increased to A$19.7 million end-March.

It was a good day for some of ASX-listed cancer therapy stocks yesterday, with three companies releasing seperate announcements that sent their share prices higher. Cancer therapy stocks Invion (ASX:IVX), Immutep (ASX:IMM), and Imugene (ASX...

During the quarter, the oncology-focused drug development company saw maiden revenue of A$5.3 million and its cash position increased to A$19.7 million end-March.

During the quarter, the oncology-focused drug development company saw maiden revenue of A$5.3 million and its cash position increased to A$19.7 million end-March. 

The company gained exclusive global rights to the drug for €1 million (A$1.6 million) upfront, €308 million (A$480 million) in milestones and a tiered single-digit royalty on sales.

ShareCafeThe Week that Was – April 19-23, 2021 We at ShareCafe understand you are busy and may not have been left with enough time to keep up with the quality content we’ve been bringing you throughout the week. To make it easier to do so,...

Kazia Therapeutics (ASX:KZA) has entered into a worldwide exclusive licensing agreement and a master services agreement with European company Evotec SE for EVT801, a small molecule, first-in-class oncology drug candidate.

Kazia Therapeutics (ASX:KZA)‘s chief executive says he could do with catching up on sleep after a “whirlwind” seven weeks in which the $185 million cancer-focused Sydney biotech completed three different cross-border licensing deals. Kazia...

Much of Kazia’s operational capacity has opened up with the inclusion of paxalisib in the GBM AGILE study, and the company believes that it can dedicate significant resources to the EVT801 program.

Kazia expects to explore potential uses of EVT801 during the clinical program, including renal cell carcinoma (kidney cancer), hepatocellular carcinoma (liver cancer) and soft tissue sarcoma.

ShareCafeKazia Licenses New Oncology Drug Candidate Kazia Therapeutics Limited (ASX: KZA; NASDAQ: KZIA), an oncology focused drug development company has announced that it has entered into a worldwide exclusive licensing agreement and a mas...

SYDNEY, April 19, 2021 /PRNewswire/ — Kazia Therapeutics Limited (ASX: KZA; NASDAQ: KZIA), an oncology-focused drug development company, is pleased to announce that it has entered into a worldwide exclusive licensing agreement and a master...

The ASX finished the day higher but the all time high reached prior to COVID-19 still eludes it. The ASX 200 closed at 7,066 points – 0.03 per cent higher than Friday – although the ASX Emerging Companies Index fell by 0.64 per cent to 2,10...

Small caps have gained again – rising for the fourth day in a row and the 10th time out of 11 sessions. The Small Ordinaries index of the 101st to 300th biggest Australian companies on Friday advanced 17.7 points, or 0.53 per cent to close...

Corporate Connect has increased the company’s share price target from A$2.25 to A$2.60 a share on the back of two recent licensing deals.

Kazia Therapeutics has executed two licensing deals in the space of a month, proving the company is capable of identifying highly attractive partners and negotiating equally attractive deals.

Uranium explorer 92 Energy (ASX:92E) is among several companies lined up to list on the ASX this or next week after bioenergy company Delorean joined the bourse yesterday. There are four IPOs timed for this week, including Delorean (ASX: DE...

Small caps have gained for a sixth straight day, even as their larger peers declined. The Small Ordinaries index of Australia’s 101st to 300th biggest companies finished the week up 6.7 points, or 0.2 per cent, to a fresh 13-year high of 3,...